Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tigecycline high-dose vs standard-dose for Klebsiella pneumoniae pneumonia
ChiCTR2000041036Phase 4Recruiting
- Sponsor
- Xuanwu Hospital
- Start
- Jul 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tigecycline in Klebsiella pneumoniae pneumonia and Multidrug-resistant Klebsiella pneumoniae (MDR-KP) (2 arms), sponsored by Xuanwu Hospital. Primary endpoint: Pathogen clearance rate. Started Jul 2020; status: recruiting.
02
Drugs
tigecycline
03
Conditions
Klebsiella pneumoniae pneumoniaMultidrug-resistant Klebsiella pneumoniae (MDR-KP)
Beyond the preview
Go deeper on ChiCTR2000041036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041036.